Tuberculosis (TB) ranks as the leading cause of death among infectious diseases in human history, claiming over a billion lives in the past two centuries alone [1, 2]. Although a number of important advances have been made to control TB in the past decade, an estimated 10 million people fell ill with TB and 1.5 million died from the disease in 2018 alone [1]. The only licensed TB vaccine, bacille Calmette–Guérin (BCG), provides partial protection against severe forms of TB in infants and young children (averting thousands of paediatric deaths annually), but fails to stop transmission of pulmonary tuberculosis in adults [3, 4]. A multidisciplinary framework is needed to guide the research needed for making economic and health impact arguments for tuberculosis vaccine development and uptake http://bit.ly/2stNDok

中文翻译：

---

评估新型结核病疫苗的全部价值的案例

结核病 (TB) 是人类历史上传染病的主要死因，仅在过去两个世纪就夺走了超过 10 亿人的生命 [1, 2]。尽管在过去十年中在控制结核病方面取得了许多重要进展，但估计仅 2018 年就有 1000 万人患上结核病，150 万人死于该病 [1]。唯一获得许可的结核病疫苗卡介苗 (BCG) 可部分保护婴儿和幼儿免受严重形式的结核病（每年避免数千名儿科死亡），但未能阻止肺结核病在成人中的传播 [3, 4 ]。需要一个多学科框架来指导为结核病疫苗开发和采用提出经济和健康影响论据所需的研究 http://bit.ly/2stNDok